Patents Assigned to Sorrento Therapeutics, Inc.
  • Publication number: 20220251168
    Abstract: The present disclosure provides dimeric antigen receptors (DAR) constructs that bind a BCMA target antigen, where the DAR construct comprises a heavy chain binding region on one polypeptide chain and a light chain binding region on a separate polypeptide chain. The two polypeptide chains that make up the dimeric antigen receptors can dimerize to form an antigen binding domain. The dimeric antigen receptors have antibody-like properties as they bind specifically to a target antigen. The dimeric antigen receptors can be used for directed cell therapy.
    Type: Application
    Filed: March 3, 2022
    Publication date: August 11, 2022
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Henry Hongjun Ji, Wenzhong Guo, Yanliang Zhang, Bei Bei Ding, Gunnar F. Kaufmann
  • Publication number: 20220183999
    Abstract: Disclosed herein are aqueous pharmaceutical compositions comprising cannabidiol, method of making such compositions, and methods of treatment using such pharmaceutical compositions.
    Type: Application
    Filed: April 3, 2020
    Publication date: June 16, 2022
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Hui Xie, Hua Wang, Henry Hongjun Ji, Jonathan D. Wang
  • Patent number: 11344709
    Abstract: A controller assembly of a fluid delivery apparatus includes a body component and a plunger component slidably coupled to the body component. The plunger is positionable between a first position in which the plunger is nearest to the body component, and a second position in which the plunger component is furthest from the body component. A bias assembly positioned between the body component and the plunger component applies a two stage force profile to the plunger component. The bias assembly includes a first and a second biasing member. In the first position, the first and second biasing members apply first and second forces profiles, respectively, to the plunger component. In the second position, the first biasing member is prevented from applying the first force profile to the plunger component, and the second biasing member applies the second force profile to the plunger component.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: May 31, 2022
    Assignee: SORRENTO THERAPEUTICS, INC.
    Inventors: Russell F. Ross, Andrew T. Baker, Luke Hagan
  • Publication number: 20220144971
    Abstract: Provided are bispecific antibody compounds having the Formula I: wherein, FAB1, FAB2, and —X— are as defined herein. The provided bispecific antibody compounds can be used a modulators of target molecules, including CD3, PSMA, CD19, CXCR5, CD33, PDL1, VEGFR2, cMet, or Axl, and are useful in the treatment of one or more conditions.
    Type: Application
    Filed: January 26, 2022
    Publication date: May 12, 2022
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Yanwen Fu, Gunnar F. Kaufmann, James T. Patterson
  • Publication number: 20220144966
    Abstract: The present disclosure provides anti-CD38 antigen-binding proteins such as fully human anti-CD38 IgG class antibodies each having an altered amino acid sequence in their heavy chain variable region and/or light chain variable region compared to their wild type parent antibody. The present disclosure provides engineered CD38 binding proteins, particularly anti-CD38 variant antibodies, or antigen-binding portions thereof, that specifically bind CD38, and uses thereof. The disclosed anti-CD38 antigen-binding proteins and antibodies have been engineered to exhibit improved characteristics compared to the parent antibody, such as improved binding to CD38 antigen, improved binding to CD38-expressing cells, and/or higher levels of cytotoxicity. The anti-CD38 variant antibodies can cross-react (bind) with cynomolgus CD38.
    Type: Application
    Filed: March 27, 2020
    Publication date: May 12, 2022
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Xia Cao, Heyue Zhou, John Dixon Gray, Barbara A. Swanson
  • Patent number: 11318202
    Abstract: There is disclosed compositions and methods relating to or derived from anti-WISP1 antibodies. More specifically, there is disclosed fully human antibodies that bind WISP1, WISP1-binding fragments and derivatives of such antibodies, and WISP1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having WISP1 related disorders or conditions. There is also disclosed a method for treating or preventing various cancers or inflammatory diseases and various diseases of the heart, bone/joints or lung.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: May 3, 2022
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Heyue Zhou, Gunnar F. Kaufmann
  • Patent number: 11311708
    Abstract: A microneedle array assembly includes a microneedle array that has a plurality of microneedles. A distribution manifold includes a fluid supply channel that is coupled in flow communication to a plurality of resistance channels. Each of the resistance channels are coupled in flow communication to a respective one of the microneedles of the microneedle array. The resistance channels have a resistance value to a fluid flow through each resistance channel that is in the range between about 5 times greater to about 100 times greater than a resistance to the fluid flow through the supply channel.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: April 26, 2022
    Assignee: SORRENTO THERAPEUTICS, INC.
    Inventors: Andrew T. Baker, Russell F. Ross
  • Publication number: 20220118105
    Abstract: There is disclosed an antibody drug conjugate (ADC) having an IgG antibody that binds to a CD38 target conjugated at a Cys site in the hinge region of an IgG antibody. There is further disclosed a method for treating multiple myeloma comprising providing an effective amount of a CD38 ADC.
    Type: Application
    Filed: November 3, 2021
    Publication date: April 21, 2022
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Tong Zhu, Alisher Khasanov, Gang Chen, Katherine Fells, Heyue Zhou, John Dixon Gray
  • Patent number: 11267905
    Abstract: Provided are bispecific antibody compounds having the Formula I: wherein, FAB1, FAB2, and —X— are as defined herein. The provided bispecific antibody compounds can be used a modulators of target molecules, including CD3, PSMA, CD19, CXCR5, CD33, PDL1, VEGFR2, cMet, or Ax1, and are useful in the treatment of one or more conditions.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: March 8, 2022
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Yanwen Fu, Gunnar F. Kaufmann, James T. Patterson
  • Patent number: 11247033
    Abstract: A transdermal drug delivery apparatus includes a receptacle having a housing and a microneedle assembly mounted to the housing. The apparatus includes a reservoir for being mounted to the receptacle. The reservoir has an interior for containing fluid for being supplied to the microneedle assembly. The apparatus is adapted so that, when the apparatus is assembled, the reservoir is configured to move relative to the microneedle assembly along a path from an outer position to an inner position. The reservoir is closer to the microneedle assembly in the inner position than in the outer position. In the outer position, the reservoir is out of fluid communication with the microneedle assembly, and in the inner position, the reservoir is in fluid communication with the microneedle assembly. The apparatus also includes a plurality of connector parts spaced apart from one another along the path.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: February 15, 2022
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Andrew T. Baker, Russell F. Ross, Elizabeth Deibler Gadsby, Luke Hagan
  • Patent number: 11242391
    Abstract: There is disclosed compositions and methods relating to or derived from anti-PD-1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-1, PD-1-binding fragments and derivatives of such antibodies, and PD-1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-1 related disorders or conditions, including various inflammatory disorders and various cancers.
    Type: Grant
    Filed: January 14, 2020
    Date of Patent: February 8, 2022
    Assignee: SORRENTO THERAPEUTICS, INC.
    Inventors: Heyue Zhou, Barbara A. Swanson, John Dixon Gray, Gunnar F. Kaufmann, Edwige Gros
  • Publication number: 20220025054
    Abstract: There is disclosed compositions and methods relating to anti-VEGFR2 antibodies. More specifically, there is disclosed fully human antibodies that bind VEGFR2, VEGFR2-binding fragments and derivatives of such antibodies, and VEGFR2-binding polypeptides comprising such fragments. Further still, there is disclosed antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having various cancers.
    Type: Application
    Filed: July 29, 2021
    Publication date: January 27, 2022
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Randy Gastwirt, Heyue Zhou, John Dixon Gray, Guodi Lu
  • Patent number: 11219721
    Abstract: An attachment band for a fluid delivery apparatus includes an annular body having a wall defining a hollow inner space, an adjacent pair of attachment apertures extending through the wall, and an indicator aperture extending through the wall opposite the pair of attachment apertures. The indicator aperture includes an indicator portion that is configured to present an indication to a user of the fluid delivery apparatus of a tightness of the attachment band. A first strap extends radially outward from the annular body of the attachment band and is substantially aligned with the attachment apertures. A second strap extends radially outward from the annular body and is substantially aligned with the indicator aperture.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: January 11, 2022
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Russell F. Ross, Andrew T. Baker, Elizabeth D. Gadsby, Luke Hagan, Aaron Peck, Alyson Yamada, Pratap Ganapathy
  • Publication number: 20220002415
    Abstract: There is disclosed compositions and methods relating to or derived from anti-CTLA4 antibodies. More specifically, there is disclosed fully human antibodies that bind CTLA4, CTLA4-antibody binding fragments and derivatives of such antibodies, and CTLA4-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring either stimulation of immune responses or suppression.
    Type: Application
    Filed: September 22, 2021
    Publication date: January 6, 2022
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: John Dixon Gray, Heyue Zhou
  • Publication number: 20220002422
    Abstract: There is disclosed compositions and methods relating to or derived from anti-c-Met antibodies. More specifically, there is disclosed fully human antibodies that bind c-Met, c-Met-binding fragments and derivatives of such antibodies, and c-Met-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having c-Met related disorders or conditions, including various inflammatory disorders and various cancers.
    Type: Application
    Filed: September 22, 2021
    Publication date: January 6, 2022
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Barbara A. Swanson, Heyue Zhou, Yan-Liang Zhang, Randy Gastwirt, John Dixon Gray
  • Patent number: 11213666
    Abstract: A method for administering a medicament to a patient includes placing a fluid delivery apparatus with the medicament in contact with a portion of the skin of said patient. A flow rate of the medicament from the fluid delivery apparatus is adjusted such that the medicament is delivered to the patient for a predetermined time period. The fluid delivery apparatus includes a controller assembly having a body component defining an axis and a plunger component slidably coupled to the body component. The plunger is positionable between a first position in which the plunger is nearest to the body component and a second position in which the plunger component is furthest from the body component. A bias assembly is positioned between the body component and the plunger component. The bias assembly is configured to apply a two stage force profile to the plunger component.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: January 4, 2022
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Russell F. Ross, Andrew T. Baker, Luke Hagan
  • Publication number: 20210395380
    Abstract: The present disclosure provides variant anti-OX40 antibodies that mimic the activity of OX4OL by behaving as an agonist against receptor OX40 to enhance T cell clonal expansion and differentiation. The variant anti-OX40 antibodies exhibit improved binding affinity for OX40 and improved agnostic activity, compared to a wild type anti-OX40 antibody (wild type 2B4 clone) from which the variant clones are derived. The variant anti-OX40 antibodies specifically bind OX40 receptors on activated T lymphocytes, stimulate proliferation of effector T cells, stimulate proliferation of effector T cells in the presence of regulatory T cells, and stimulate production of at least one cytokine from effector T cells.
    Type: Application
    Filed: August 23, 2021
    Publication date: December 23, 2021
    Applicant: Sorrento Therapeutics, Inc.
    Inventor: Min Soo Kim
  • Publication number: 20210393515
    Abstract: Disclosed herein are methods of administering resiniferatoxin (RTX) perineurally for treatment of maladaptive pain, and compositions for use in such methods.
    Type: Application
    Filed: June 11, 2021
    Publication date: December 23, 2021
    Applicant: Sorrento Therapeutics, Inc.
    Inventor: Alexis Nahama
  • Publication number: 20210388097
    Abstract: The present disclosure provides BCMA binding proteins, particularly anti-BCMA antibodies, or antigen-binding portions thereof, that specifically bind BCMA and uses thereof. In one embodiment, the anti-BCMA antibody comprises an antigen binding portion that binds a human BCMA epitope and blocks binding (e.g, inhibits binding) of human APRIL and/or human BAFF to the human BCMA epitope. Various aspects of the anti-BCMA antibodies relate to antibody fragments, single-chain antibodies, pharmaceutical compositions, nucleic acids, recombinant expression vectors, host cells, and methods for preparing and using such anti-BCMA antibodies. Methods for using the anti-BCMA antibodies include in vitro and in vivo methods for binding BCMA, detecting BCMA and treating diseases associated with BCMA over-expression.
    Type: Application
    Filed: August 25, 2021
    Publication date: December 16, 2021
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Heyue Zhou, Xia Cao
  • Patent number: 11191845
    Abstract: There is disclosed an antibody drug conjugate (ADC) having an IgG antibody that binds to a CD38 target conjugated at a Cys site in the hinge region of an IgG antibody. There is further disclosed a method for treating multiple myeloma comprising providing an effective amount of a CD38 ADC.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: December 7, 2021
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Tong Zhu, Alisher Khasanov, Gang Chen, Katherine Fells, Heyue Zhou, John Dixon Gray